Pulmonary Infiltrates in Neutropenic Patients With Acute Leukemia During Chemotherapy

Outcome and Prognostic Factors

¹ From the Department of Internal Medicine, University of Bonn, Bonn, Germany
² From the Department of Radiology, University of Bonn, Bonn, Germany
³ From the Institute of Medical Microbiology and Immunology, University of Bonn, Bonn, Germany

Priv-Doz Dr med Santiago Ewig, Medizinische Universitätsklinik und Poliklinik, Innere Medizin/Kardiologie und Pneumologie, Sigmund Freud Str, 25, 53105 Bonn, Germany

Study objective: To determine predictors of mortality from pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy, and the significance of those factors related to the underlying malignancy and its therapy as well as of those related to the severity of the illness associated with pulmonary infiltrates.

Design: A historical cohort study.

Setting: A university teaching hospital and tertiary referral center.

Patients and methods: Overall, 53 patients with neutropenia during chemotherapy and with first episodes of pulmonary infiltrates during a 4-year period were studied. Prognostic analysis included 38 variables. Multivariate analyses were performed by logistic regression.

Results: The survival rate from pneumonia was 57% (30/53). The following eight parameters were significantly associated with death in univariate analysis: comorbidity present; development of "late" pulmonary infiltrates (14 days after hospital admission); heart rate 100 beats/min; a ratio heart rate/systolic blood pressure (HR/SBP) 1.2; urea nitrogen >7 mmol/L; radiographic score 3; neutropenia <1.0x10⁹/L at the treatment end point; and failed complete remission. In a multivariate model including only parameters available at diagnosis of pulmonary infiltrates, the presence of a ratio HR/SBP 1.2 and of a radiographic score 3 remained independently associated with death. In a second model also including the evolutionary parameter neutropenia 1.0x10⁹/L at the treatment end point, both parameters remained significant together with neutropenia <1.0x10⁹/L at the treatment end point. The presence of a ratio HR/SBP 1.2 was a strong marker of early death.

Conclusion: Both therapy- and malignancy-associated neutropenia as well as the severity of illness associated with pulmonary infiltrates are independent prognostic factors. Patients with a ratio HR/SBP 1.2 at diagnosis of pulmonary infiltrates suffer from potentially reversible acute illness, are at risk for early death and, therefore, may be appropriate candidates for treatment in an ICU.

Key Words: hematologic malignancy • infiltrates • pneumonia • prognosis

Submitted on July 1, 1997
Accepted on February 19, 1998

This article has been cited by other articles:

				A. Holley, D. Mayes, and R. Browning A 40-Year-Old Man With Neutropenic Fever and Lobar Consolidation Chest, March 1, 2008; 133(3): 816 - 819. [Full Text] [PDF]

				R. Eibel, P. Herzog, O. Dietrich, C. T. Rieger, H. Ostermann, M. F. Reiser, and S. O. Schoenberg Pulmonary Abnormalities in Immunocompromised Patients: Comparative Detection with Parallel Acquisition MR Imaging and Thin-Section Helical CT Radiology, October 10, 2006; (2006) 2413042056. [Abstract] [Full Text]

				A. Rano, C. Agusti, N. Benito, M. Rovira, J. Angrill, T. Pumarola, and A. Torres Prognostic Factors of Non-HIV Immunocompromised Patients With Pulmonary Infiltrates* Chest, July 1, 2002; 122(1): 253 - 261. [Abstract] [Full Text] [PDF]